NICE decision is key milestone expanding access to patients in the United Kingdom ATLANTA , June 20, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal

A single ILUVIEN implant significantly delayed recurrence and reduced uveitis symptoms upon recurrence compared to active control arm Recently approved in Europe , ILUVIEN is expected to launch in certain EU countries during the second half of 2019 ATLANTA , June 06, 2019 (GLOBE NEWSWIRE) --

Pilot program to be initiated in four U.S. cities leveraging radio, print and social media channels, with potential for future expansion ILUVIEN’s CONTINUOUS MICRODOSING™ delivery enables patients diagnosed with diabetic macular edema (DME) to maintain vision longer with fewer intra-ocular

ATLANTA , May 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that President and CEO, Rick Eiswirth will present a corporate overview and meet with investors at the

First Quarter and Recent Company Highlights: Global revenue up 34% versus Q1 2018 Regulatory approval obtained for ILUVIEN ® in 17 EU countries for the treatment of Non-Infectious Posterior Uveitis Samer Kaba , M.D. appointed to new position of Chief Medical Officer National pricing and

Conference Call to be held Tuesday April 30, 2019 at 9:00am Eastern Time ATLANTA, (April 23, 2019) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that it will report first quarter 2019

ATLANTA, (April 23, 2019) – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that clinical data for ILUVIEN ® will be featured in 15 posters and one podium presentation at the Association for

ATLANTA, April 4, 2019 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced an expansion of its leadership team with the appointment of Samer Kaba, MD as Chief Medical Officer, effective April

Indication for treatment of non-infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of inflammation Regulatory process to now enter the national phase in which each member state finalizes the label to

Kuwait added to the growing number of countries with approval for ILUVIEN in the Middle East ATLANTA, March 21, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera) , a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN has